Isatuximab (Isatuximab) manufacturer information and purchase price

Isatuximab (Isatuximab) is a monoclonal antibody targeting CD38 and is mainly used for the treatment of hematological malignancies such as multiple myeloma. The drug is developed and produced by an internationally renowned biopharmaceutical company with a complete clinical research and regulatory approval background. Its research and development and production follow strict quality control standards to ensure the safety and efficacy of the drugs. After its domestic launch, isatuximab is mainly available through regular hospitals and designated pharmacies, and patients need to purchase it with a doctor's prescription to ensure a reliable source of the drug.

In the domestic market, isatuximab has been included in medical insurance, and patients can be reimbursed according to medical insurance policies. The current domestic price is about more than 12,000 yuan per dose, which is a huge financial burden for patients who require long-term treatment. Before purchasing drugs, patients should fully evaluate their own financial conditions and formulate a reasonable medication plan based on doctor's recommendations to ensure the continuity and effect of treatment.

In overseas markets, the price of the original drug of isatuximab is approximately3,000 more than US dollars per dose, which is significantly higher than the domestic selling price. This shows that although domestically marketed drugs are not included in medical insurance, they still have certain economic advantages compared with overseas imported drugs. Currently, there is no generic version of this drug, and patients cannot obtain relatively low-cost alternative drugs from other sources, so purchasing through formal channels is particularly important.

Overall, the domestic launch of isatuximab provides a new treatment option for multiple myeloma patients, but its high price requires patients to arrange their medication rationally under the guidance of a doctor. Purchasing through regular hospitals not only ensures the quality and safety of the drugs, but also facilitates doctors' efficacy evaluation and follow-up management. In the future, with the adjustment of medical insurance policies or the launch of generic drugs, patient medication costs may be further reduced.

References:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-isatuximab-irfc-multiple-myeloma